The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The leadership change comes at the end of a week in which the California-based toymaker landed squarely in the crosshairs of ...

Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds.

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Kenvue named Kellanova Chief Financial Officer Amit Banati to that role at the over-the-counter drug maker, replacing current financial chief Paul Ruh, effective May 12. Banati has worked in executive ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSofya Tsinis - Head of Investor RelationsThibaut ...

Discover Kenvue's Q1 2025 earnings insights—strategic growth, tariff mitigation, innovation focus, and supply chain resilience to drive performance this year.

May 8 (Reuters) - Kenvue (KVUE.N), opens new tab on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a $150 million impact from ...

Kenvue KVUE1.58%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...